Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise noted.

Immunoassay is the largest subdivision in in vitro diagnosis and is in rapid develop-ment, in which chemiluminescence has gradually replaced enzyme-linked immuno-sorbent assay as the mainstream immune diagnosis in China.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with the Kenyan Government through the National Cancer Institute-Kenya to advance access to critical cancer diagnostics for women in Kenya. Through this program, BD continues to drive its commitment toward progress of advancing health equity to underserved communities around the world.

Next-generation sequencing (NGS) is a high-throughput method for DNA sequencing that has largely superseded traditional first-generation sequencing methods.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

An analysis conducted by an international research team has identified 13 biomarkers that may improve the accuracy of predicting the risk of cardiovascular disease (CVD) in people with type 2 diabetes.

The House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party said on Thursday that it has introduced a new bill to ban the use of federal funding on "foreign adversary biotech companies," including China's BGI Group.

Recently, the internationally renowned Top Employers Institute released the "China Top Employers 2024" list.

DiaSorin on Thursday said it has submitted for US Food and Drug Administration approval an immunoassay for the early identification of Lyme disease.

Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced its selection of Microsoft as a technology partner for its SG OneSystem™ business in London, UK, on January 23 to realize 'a world free from all diseases.'

Abbott Laboratories (NYSE:ABT) posted higher sales of $10.24 billion in the fourth quarter, despite continued soft demand for the company’s Covid-19 testing equipment, beating the consensus of $10.18 billion.

The European Commission (EC) has proposed an extension of the transition period for the IVDR, aiming to maintain the availability of essential healthcare products and ensure patient care.

China's medical device industry has grown at a compound annual growth rate of 10.54% over the past five years and has become the second largest market in the world.

New research suggests a combination of molecular profiling on tumor tissue and corresponding circulating tumor DNA (ctDNA) samples can provide clinically actionable clues that may be missed using either approach alone, particularly for individuals with breast cancer or non-small cell lung cancer (NSCLC).

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.